These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 30721982)
1. Antibodies Against Egg- and Cell-Grown Influenza A(H3N2) Viruses in Adults Hospitalized During the 2017-2018 Influenza Season. Levine MZ; Martin ET; Petrie JG; Lauring AS; Holiday C; Jefferson S; Fitzsimmons WJ; Johnson E; Ferdinands JM; Monto AS J Infect Dis; 2019 May; 219(12):1904-1912. PubMed ID: 30721982 [TBL] [Abstract][Full Text] [Related]
2. Low population serum microneutralization antibody titer against the predominating influenza A(H3N2) N121K virus during the severe influenza summer peak of Hong Kong in 2017. Zhu H; Lee ACY; Li C; Mak WWN; Chen YY; Chan KH; Zhang AJX; Fung WF; Zhang RQ; Fung YF; Poon RWS; Lam JY; Tam S; Hung IFN; Chen H; Yuen KY; To KKW Emerg Microbes Infect; 2018 Mar; 7(1):23. PubMed ID: 29511175 [TBL] [Abstract][Full Text] [Related]
3. Neutralizing Antibody Responses to Antigenically Drifted Influenza A(H3N2) Viruses among Children and Adolescents following 2014-2015 Inactivated and Live Attenuated Influenza Vaccination. Levine MZ; Martin JM; Gross FL; Jefferson S; Cole KS; Archibald CA; Nowalk MP; Susick M; Moehling K; Spencer S; Chung JR; Flannery B; Zimmerman RK Clin Vaccine Immunol; 2016 Oct; 23(10):831-839. PubMed ID: 27558294 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs. Kishida N; Fujisaki S; Yokoyama M; Sato H; Saito R; Ikematsu H; Xu H; Takashita E; Tashiro M; Takao S; Yano T; Suga T; Kawakami C; Yamamoto M; Kajiyama K; Saito H; Shimada S; Watanabe S; Aoki S; Taira K; Kon M; Lin JH; Odagiri T Clin Vaccine Immunol; 2012 Jun; 19(6):897-908. PubMed ID: 22492743 [TBL] [Abstract][Full Text] [Related]
5. Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses following influenza vaccination. Liu F; Gross FL; Jefferson SN; Holiday C; Bai Y; Wang L; Zhou B; Levine MZ J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33690218 [TBL] [Abstract][Full Text] [Related]
6. The Household Influenza Vaccine Effectiveness Study: Lack of Antibody Response and Protection Following Receipt of 2014-2015 Influenza Vaccine. Petrie JG; Malosh RE; Cheng CK; Ohmit SE; Martin ET; Johnson E; Truscon R; Eichelberger MC; Gubareva LV; Fry AM; Monto AS Clin Infect Dis; 2017 Oct; 65(10):1644-1651. PubMed ID: 29020179 [TBL] [Abstract][Full Text] [Related]
7. Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017-2018. Belongia EA; Levine MZ; Olaiya O; Gross FL; King JP; Flannery B; McLean HQ Vaccine; 2020 Mar; 38(15):3121-3128. PubMed ID: 32145994 [TBL] [Abstract][Full Text] [Related]
8. Antibody response to sequential vaccination with cell culture, recombinant, or egg-based influenza vaccines among U.S. adults. Boyce TG; Levine MZ; McClure DL; King JP; Flannery B; Nguyen HQ; Belongia EA Hum Vaccin Immunother; 2024 Dec; 20(1):2370087. PubMed ID: 38982712 [TBL] [Abstract][Full Text] [Related]
9. Differential Antibody Recognition of H3N2 Vaccine and Seasonal Influenza Virus Strains Based on Age, Vaccine Status, and Sex in the 2017-2018 Season. Ursin RL; Liu H; Powell HR; Westerbeck JW; Shaw-Saliba K; Sylvia KE; Fenstermacher KJ; Mehoke T; Thielen P; Rothman RE; Pekosz A; Klein SL J Infect Dis; 2020 Sep; 222(8):1371-1382. PubMed ID: 32496543 [TBL] [Abstract][Full Text] [Related]
10. Comparison of immunogenicity between candidate influenza A(H3N2) virus vaccine strains in Japan: A randomized controlled trial using a monovalent vaccine of A/Saitama/103/2014 (CEXP-002) and A/Hong Kong/4801/2014 (X-263). Kase T; Inoue M; Morikawa S; Kumashiro H; Hiroi S; Nakata K; Ito K; Ishibashi M; Tsuru T; Irie S; Maeda A; Ohfuji S; Fukushima W; Hirota Y Vaccine; 2020 Sep; 38(42):6524-6532. PubMed ID: 32873406 [TBL] [Abstract][Full Text] [Related]
11. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses. Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350 [TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of antibody response to 2018-19 cell-based vs. egg-based quadrivalent inactivated influenza vaccine in children. Moehling KK; Zimmerman RK; Nowalk MP; Jeng Lin C; Martin JM; Alcorn JF; Susick M; Burroughs A; Holiday C; Flannery B; Levine MZ Vaccine; 2020 Jul; 38(33):5171-5177. PubMed ID: 32580919 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of correlates of protection against influenza A(H3N2) and A(H1N1)pdm09 infection: Applications to the hospitalized patient population. Petrie JG; Martin ET; Truscon R; Johnson E; Cheng CK; McSpadden EJ; Malosh RE; Lauring AS; Lamerato LE; Eichelberger MC; Ferdinands JM; Monto AS Vaccine; 2019 Feb; 37(10):1284-1292. PubMed ID: 30738647 [TBL] [Abstract][Full Text] [Related]
14. Isolation of an Egg-Adapted Influenza A(H3N2) Virus without Amino Acid Substitutions at the Antigenic Sites of Its Hemagglutinin. Kuwahara T; Takashita E; Fujisaki S; Shirakura M; Nakamura K; Kishida N; Takahashi H; Suzuki N; Kawaoka Y; Watanabe S; Odagiri T Jpn J Infect Dis; 2018 May; 71(3):234-238. PubMed ID: 29709975 [TBL] [Abstract][Full Text] [Related]
15. An updated influenza A(H3N2) vaccine generates limited antibody responses to previously encountered antigens in children. Florek KR; Campos LM; Braun KM; McLean HQ; King JP; Flannery B; Belongia EA; Friedrich TC Vaccine; 2018 Jan; 36(5):758-764. PubMed ID: 29249543 [TBL] [Abstract][Full Text] [Related]
16. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. Skowronski DM; Janjua NZ; De Serres G; Sabaiduc S; Eshaghi A; Dickinson JA; Fonseca K; Winter AL; Gubbay JB; Krajden M; Petric M; Charest H; Bastien N; Kwindt TL; Mahmud SM; Van Caeseele P; Li Y PLoS One; 2014; 9(3):e92153. PubMed ID: 24667168 [TBL] [Abstract][Full Text] [Related]
17. Lack of neutralizing antibodies against influenza A viruses in adults during the 2022/2023 winter season - a serological study using retrospective samples collected in Hong Kong. Liang W; Lv H; Chen C; Sun Y; Hui DS; Mok CKP Int J Infect Dis; 2023 Oct; 135():1-4. PubMed ID: 37481108 [TBL] [Abstract][Full Text] [Related]
18. Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons. Hiroi S; Morikawa S; Nakata K; Maeda A; Kanno T; Irie S; Ohfuji S; Hirota Y; Kase T Hum Vaccin Immunother; 2015; 11(2):386-90. PubMed ID: 25692378 [TBL] [Abstract][Full Text] [Related]
19. Comparability of Titers of Antibodies against Seasonal Influenza Virus Strains as Determined by Hemagglutination Inhibition and Microneutralization Assays. Heeringa M; Leav B; Smolenov I; Palladino G; Isakov L; Matassa V J Clin Microbiol; 2020 Aug; 58(9):. PubMed ID: 32493784 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of a qualified MDCK cell line for virus isolation to develop cell-based influenza vaccine viruses with appropriate antigenicity. Harada Y; Takahashi H; Fujimoto T; Horikoshi F; Chida S; Tanaka K; Minari K; Tanimoto Y; Fujisaki S; Miura H; Nakauchi M; Shimasaki N; Suzuki Y; Arita T; Hamamoto I; Yamamoto N; Hasegawa H; Odagiri T; Tashiro M; Nobusawa E Vaccine; 2024 Oct; 42(23):126242. PubMed ID: 39213922 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]